| TAISHO PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120040898 | PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition comprising a combination of
| 02-16-2012 |
| 20120028982 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE - A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] | 02-02-2012 |
| 20120022164 | EXTERNAL PREPARATION COMPRISING PROSTAGLANDIN DERIVATIVE - Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): | 01-26-2012 |
| 20120022064 | DIHYDROQUINOLINONE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 01-26-2012 |
| 20120010414 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES - The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder: | 01-12-2012 |
| 20120004232 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE - A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration | 01-05-2012 |
| 20110306759 | 4-ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLT1 INHIBITORS - The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. | 12-15-2011 |
| 20110288293 | ISOQUINOLINE DERIVATIVE - A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis. | 11-24-2011 |
| 20110269960 | TRIAZOLE DERIVATIVE - An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P | 11-03-2011 |
| 20110237791 | 2-PYRIDONE COMPOUNDS - A 2-pyridone compound represented by the formula [1]: | 09-29-2011 |
| 20110237784 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS - A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even | 09-29-2011 |
| 20110213143 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY - Provided are compounds having superior TAFIa inhibitory activity. Specifically, there are provided compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: | 09-01-2011 |
| 20110178304 | 7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE - Problem To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. | 07-21-2011 |
| 20110152239 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE - The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14 and C 16. | 06-23-2011 |
| 20110137031 | PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES - An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. | 06-09-2011 |
| 20110130364 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP - An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. | 06-02-2011 |
| 20110124862 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS - [Problem to be Solved] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for δ receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. | 05-26-2011 |
| 20110098469 | 1-THIO-D-GLUCITOL DERIVATIVES - The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate. | 04-28-2011 |
| 20110081415 | COATING APPARATUS - A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer. | 04-07-2011 |
| 20110065934 | METHOD OF PRODUCING BICYCLO[3.1.0] HEXANE DERIVATIVE USING ENZYME - Production of a bicyclo[3.1.0]hexane derivative, useful as a metabotropic glutamate receptor modulator, becomes possible by a production method that includes converting a compound represented by Formula (II) into a compound represented by Formula (III) by reaction with an acyl group donor in the presence of a microorganism-derived enzyme, without using an expensive optically active trans hydroxy ester as a starting material and without employing a fluorination reaction requiring an ultralow temperature reaction. Furthermore, since asymmetric synthesis can be carried out in a stage closer to the final product, the production method is useful as a production method that can mass produce a bicyclo[3.1.0]hexane derivative. | 03-17-2011 |
| 20110065668 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 03-17-2011 |
| 20110065667 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 03-17-2011 |
| 20100298561 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE - A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] | 11-25-2010 |
| 20100298557 | PYRAZOLOPYRIMIDINE COMPOUND - Disclosed is a novel compound having Syk and/or Abl inhibitory activities, which is useful for prevention/treatment of allergic diseases, autoimmune diseases, arthritides and cancers. Specifically disclosed is a pyrazolopyrimidine compound represented by the formula [I] or [III] below, a tautomer thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvent of any of them. | 11-25-2010 |
| 20100267687 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 10-21-2010 |
| 20100249417 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME - Disclosed is 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)amino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one monohydrate, which has strong antibacterial activity. The compound is highly safe and useful as an original drug for pharmaceutical preparations. Also disclosed is a method which is useful for producing 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)amino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one monohydrate. | 09-30-2010 |
| 20100234594 | INHIBITOR OF BINDING OF S1P1 - A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: | 09-16-2010 |
| 20100216787 | THIAZOLE DERIVATIVE - A thiazolylimidazole derivative represented by the formula | 08-26-2010 |
| 20100204331 | PROSTAGLANDIN DERIATIVE-CONTAINING AQUEOUS LIQUID PREPARATION - Provided is an aqueous liquid preparation comprising: (a) any one of a prostaglandin derivative being represented by the following formula (I), a pharmaceutically acceptable salt thereof and a hydrate thereof; and (b) at least one polyol of glycerin, propylene glycol, dipropylene glycol and 1,3-butylene glycol. | 08-12-2010 |
| 20100204320 | PHARMACEUTICALS FOR XEROSIS - A method for preventing or treating xerosis by applying a prostaglandin D receptor selective agonist to a mammal. | 08-12-2010 |
| 20100190980 | PYRAZINAMIDE COMPOUND - Disclosed is a pyrazinamide compound represented by the formula (1), a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, or a solvate of the compound or the tautomer, stereoisomer or pharmaceutically acceptable salt thereof, which has an excellent GK-activating activity and is therefore useful as a medicinal agent. (1) wherein R | 07-29-2010 |
| 20100179325 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY - The present invention provides compounds having excellent 11β-HSD1 inhibitory activity. | 07-15-2010 |
| 20100168418 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF - A nitrogen-containing heterocyclic compound represented by the general formula: wherein the dashed line represents a single bond or a double bond; R | 07-01-2010 |
| 20100151054 | EMULSION LOTION - An emulsion lotion composition including
| 06-17-2010 |
| 20100081825 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE - Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) | 04-01-2010 |
| 20100069460 | 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE - A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: | 03-18-2010 |
| 20100022604 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ALOPECIA - Disclosed is a novel therapeutic agent which is useful for the prevention or treatment of alopecia. Specifically disclosed is a prophylactic or therapeutic agent for alopecia, which comprises 1-[2-((2S)-2-{5-[(3,4-dimethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl}pyrrolidin-1-yl)-1,1-difluoro-2-oxoethyl]-3,3,5,5-tetramethylcyclohexanol as an active ingredient. | 01-28-2010 |
| 20100022460 | C-PHENYL GLYCITOL COMPOUND - Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof | 01-28-2010 |
| 20100004465 | C-PHENYL 1-THIOGLUCITOL COMPOUND - C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: | 01-07-2010 |
| 20090306408 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative - A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration | 12-10-2009 |
| 20090291940 | AMINOPYRROLIDINE COMPOUND - Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC | 11-26-2009 |
| 20090234162 | Radioactive Halogen-Labeled Phenyloxyaniline Derivatives - A radioactive halogen-labeled phenyoxyaniline derivative represented by the following formula: wherein R | 09-17-2009 |
| 20090198063 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF - Disclosed is a compound represented by the general formula: [wherein R | 08-06-2009 |
| 20090182144 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE - The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P | 07-16-2009 |
| 20090155187 | DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA - To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress. | 06-18-2009 |
| 20090131438 | Triazole derivative - A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between S1P and its receptor Edg-1(S1P | 05-21-2009 |
| 20090111835 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP - An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. | 04-30-2009 |
| 20090088395 | CLARITHROMYCIN OR SALT THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF PULMONARY ALVEOLI - For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof. | 04-02-2009 |
| 20090076253 | MACROLIDE DERIVATIVES - Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD). | 03-19-2009 |
| 20080318923 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle - It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective. | 12-25-2008 |
| 20080312435 | Imine Compound - An imine compound represented by the formula: | 12-18-2008 |
| 20080306080 | NEUTROPHILIA INHIBITOR - To provide an antineutrophilia agent effective for treatment of development and progress of acute infections, collagen diseases (chronic rheumatoid arthritis, Wegener's granulomatosis and Behcet's disease), chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary emphysema, small airway disease, gout, Cushing's syndrome, myelofibrosis, neoplastic neutrophilia, polycythemia vera and diseases caused by administration of steroid drugs. | 12-11-2008 |
| 20080280928 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists - [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for δ receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.
| 11-13-2008 |
